

Kevin ten Haaf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3181/publications.pdf>

Version: 2024-02-01

53
papers

5,130
citations

201385

27
h-index

214527

47
g-index

54
all docs

54
docs citations

54
times ranked

4625
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. <i>New England Journal of Medicine</i> , 2020, 382, 503-513.	13.9	1,836
2	Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. <i>Lancet Oncology</i> , The, 2014, 15, 1332-1341.	5.1	424
3	Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2014, 160, 311.	2.0	377
4	Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. <i>Lancet Oncology</i> , The, 2014, 15, 1342-1350.	5.1	294
5	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. <i>PLoS Medicine</i> , 2017, 14, e1002277.	3.9	216
6	Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. <i>Thorax</i> , 2017, 72, 48-56.	2.7	212
7	Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. <i>Lancet Oncology</i> , The, 2016, 17, 907-916.	5.1	183
8	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 988.	3.8	181
9	PL02.05 Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised-Controlled Population Based Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, S185.	0.5	177
10	Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. <i>PLoS Medicine</i> , 2017, 14, e1002225.	3.9	114
11	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. <i>Annals of Internal Medicine</i> , 2019, 171, 796.	2.0	81
12	Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 154-161.	1.1	77
13	Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results. <i>JAMA Network Open</i> , 2019, 2, e190204.	2.8	70
14	Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States. <i>Annals of the American Thoracic Society</i> , 2020, 17, 186-194.	1.5	70
15	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. <i>Journal of the National Cancer Institute</i> , 2020, 112, 466-479.	3.0	67
16	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. <i>Cancer</i> , 2014, 120, 1713-1724.	2.0	65
17	Lung cancer screening: latest developments and unanswered questions. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 749-761.	5.2	64
18	Risk stratification based on screening history: the NELSON lung cancer screening study. <i>Thorax</i> , 2017, 72, 819-824.	2.7	54

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smokingâ€”A modelling study. <i>Lung Cancer</i> , 2018, 121, 61-69.	0.9	49
20	Disparities of National Lung Cancer Screening Guidelines in the US Population. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1136-1142.	3.0	48
21	Comparing Benefits from Many Possible Computed Tomography Lung Cancer Screening Programs: Extrapolating from the National Lung Screening Trial Using Comparative Modeling. <i>PLoS ONE</i> , 2014, 9, e99978.	1.1	38
22	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. <i>International Journal of Cancer</i> , 2017, 140, 2436-2443.	2.3	36
23	Personalising lung cancer screening: An overview of riskâ€”stratification opportunities and challenges. <i>International Journal of Cancer</i> , 2021, 149, 250-263.	2.3	36
24	Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening Study. <i>Journal of Thoracic Oncology</i> , 2015, 10, 747-753.	0.5	34
25	Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the Methodology. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	34
26	Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1285-1291.	0.5	31
27	Overdiagnosis in lung cancer screening: why modelling is essential. <i>Journal of Epidemiology and Community Health</i> , 2015, 69, 1035-1039.	2.0	31
28	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. <i>JAMA Oncology</i> , 2021, 7, 1833.	3.4	29
29	All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study. <i>Cancer Medicine</i> , 2019, 8, 6127-6138.	1.3	27
30	Implementation of lung cancer screening: what are the main issues?. <i>Translational Lung Cancer Research</i> , 2021, 10, 1050-1063.	1.3	20
31	Treatment capacity required for full-scale implementation of lung cancer screening in the United States. <i>Cancer</i> , 2019, 125, 2039-2048.	2.0	19
32	Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study. <i>Thorax</i> , 2019, 74, 247-253.	2.7	18
33	Clinically detected non-aggressive lung cancers: implications for overdiagnosis and overtreatment in lung cancer screening. <i>Thorax</i> , 2018, 73, 407-408.	2.7	16
34	Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer. <i>Pharmacoeconomics</i> , 2020, 38, 1187-1200.	1.7	16
35	Selection of eligible participants for screening for lung cancer using primary care data. <i>Thorax</i> , 2022, 77, 882-890.	2.7	13
36	Low dose CT screening for lung cancer. <i>BMJ: British Medical Journal</i> , 2017, 359, j5742.	2.4	10

#	ARTICLE	IF	CITATIONS
37	Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates. <i>Lung Cancer</i> , 2020, 139, 200-206.	0.9	9
38	Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 653-660.	1.1	9
39	Lung cancer screening: enhancing risk stratification and minimising harms by incorporating information from screening results. <i>Thorax</i> , 2019, 74, 825-827.	2.7	8
40	Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	7
41	Extrapolation of pre-screening trends: Impact of assumptions on overdiagnosis estimates by mammographic screening. <i>Cancer Epidemiology</i> , 2016, 42, 147-153.	0.8	6
42	Uptake of minimally invasive surgery and stereotactic body radiation therapy for early stage non-small cell lung cancer in the USA: an ecological study of secular trends using the National Cancer Database. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000603.	1.2	6
43	Targeted screening for lung cancer is here but who do we target and how?. <i>Thorax</i> , 2020, 75, 617-618.	2.7	5
44	Modeling Strategies to Optimize Cancer Screening in USPSTF Guidelineâ€™Noncompliant Women. <i>JAMA Oncology</i> , 2021, 7, 885.	3.4	5
45	Methods for individualized assessment of absolute risk in case-control studies should be weighted carefully. <i>European Journal of Epidemiology</i> , 2016, 31, 1067-1068.	2.5	3
46	Risk-Targeted Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2018, 169, 199.	2.0	3
47	Risk-based lung cancer screening eligibility criteria: towards implementation. <i>Lancet Oncology</i> , The, 2022, 23, 13-14.	5.1	2
48	Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses. <i>JAMA Oncology</i> , 2016, 2, 277.	3.4	0
49	Re: Think before you leap. <i>International Journal of Cancer</i> , 2018, 142, 1507-1509.	2.3	0
50	P1.11-03 Disparities and National Lung Cancer Screening Guidelines in the U.S. Population. <i>Journal of Thoracic Oncology</i> , 2019, 14, S515-S516.	0.5	0
51	Confronting the burden of tobacco-related lung cancer in Europe in the next decades. <i>Lancet Regional Health - Europe</i> , The, 2021, 4, 100085.	3.0	0
52	Towards personalized lung cancer CT screening in Europe. , 2020, , .		0
53	Informing Patient Surveillance for the Growing Number of Survivors of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2022, 17, 345-347.	0.5	0